Melita Tate
Internal Medicine · Tulsa, OKNPI 1740289966
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,601 of the $4,888 with a category attached, or 73.7%. Modernatx, Inc. accounts for 94.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $3,280 and has fallen 94.7% since, to $174 in 2025.
Across 39 payments — averaging $125.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$5K
- AstraZeneca$81
- Novo Nordisk$41
- Alkermes, Inc.$41
- Acella Pharmaceuticals, LLC$34
- Lilly USA, LLC$18
- plus $45 from 3 others
Across 4,347 payments — averaging $2103.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$7.9M
- Eli Lilly$611K
- AstraZeneca$393K
- Evofem Biosciences, Inc.$110K
- H. Lundbeck A S$82K
- Swing Therapeutics, Inc.$12K
- plus $3K from 1 others
What the payments were for
- Travel & lodging$3,60174%
- Food & beverage$1,28726%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 24 | $4,627 |
| AstraZeneca | 5 | $81 |
| Novo Nordisk | 2 | $41 |
| Alkermes, Inc. | 2 | $41 |
| Acella Pharmaceuticals, LLC | 2 | $34 |
| Lilly USA, LLC | 1 | $18 |
| Amgen | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $14 |
How this compares
$4,888 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 19 | $19,428 |
| OzempicSemaglutide | 12 | $11,166 |
| JanuviaSitagliptin Phosphate | 11 | $9,222 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,181 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 61 | $948 |
| Tramadol Hcl | 30 | $343 |
| ProgesteroneProgesterone, Micronized | 16 | $306 |
| Pregabalin | 43 | $303 |
| Potassium Chloride | 14 | $289 |
| Oxycodone Hcl | 13 | $255 |
| Eszopiclone | 15 | $190 |
| Levothyroxine Sodium | 24 | $185 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 13 | $181 |
| Atorvastatin Calcium | 14 | $178 |
| Metformin Hcl ErMetformin Hcl | 16 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $18 | $19,42819 claims |
| Novo NordiskOzempic | $41 | $11,16612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Tulsa
- Jesse RichardsTulsa$279K
- Madhuri LadTulsa$173K
- Stacy ChronisterTulsa$163K
- Layth Al AttarTulsa$35K
- Gerard McNultyTulsa$27K
- Peter LantzTulsa$23K
- Sudip TripathyTulsa$21K
- John RuffingTulsa$21K
- Joseph ReeseTulsa$18K
- Mark GallesTulsa$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.